Efficacy of Pembrolizumab in Key Subgroups of Patients with Advanced NSCLC

被引：0
|
作者：
Hellmann, Matthew D. [1 ]
Garon, Edward B. [2 ]
Gandhi, Leena [3 ]
Hui, Rina [4 ]
Zhang, Jin [5 ]
Rangwala, Reshma [5 ]
Lubiniecki, Gregory [5 ]
Rizvi, Naiyer A. [6 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Univ Sydney, Westmead Hosp, Westmead, NSW 2145, Australia
[5] Merck & Co Inc, Kenilworth, NJ USA
[6] Columbia Univ, New York, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
pembrolizumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MINI03.05
引用
收藏
页码：S270 / S270
页数：1
相关论文
共 50 条
  • [1] Predictive factors of efficacy to pembrolizumab in advanced NSCLC patients with high PD-L1 expression.
    Piedra, A.
    Barba Joaquin, A.
    Mosquera Martinez, J.
    Fernandez Bruno, M.
    Cordeiro Gonzalez, P.
    Sullivan, I. G.
    Riudavets Melia, M.
    Aguado Sorolla, M.
    Gallardo Melo, P.
    Martin Cullell, B.
    Gavira, J.
    Tapia, J. C.
    Romano, A.
    Bosma, F.
    Sanchez Del Rio, S.
    Sanz Beltran, J.
    Molina Perez, M. A.
    Serra Lopez, J.
    Garcia Campelo, M. R.
    Majem Tarruella, M.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1053 - S1053
  • [2] A single centre audit of the use of pembrolizumab immunotherapy in patients with advanced NSCLC
    Winn, E.
    Hughes, A.
    Gardiner, J.
    Simmons, T.
    McMenemin, R.
    Greystoke, A.
    [J]. LUNG CANCER, 2018, 115 : S37 - S37
  • [3] Pembrolizumab for Advanced NSCLC: Patterns of Response and Progression
    Lee, Jenny H.
    Park, John J.
    Gebski, Val
    Tangunan, Raymond
    Chan, Matthew M.
    Gaol, Bo
    Hui, Rina
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S407 - S407
  • [4] Risk of pneumonitis in patients with advanced NSCLC treated with pembrolizumab in KEYNOTE-001
    Ahn, M. -J.
    Gandhi, L.
    Hamid, O.
    Hellmann, M. D.
    Garon, E. B.
    Ramalingam, S. S.
    Lubiniecki, G. M.
    Zhang, J.
    Piperdi, B.
    Hui, R.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 140 - 140
  • [5] Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC
    Pengfei Cui
    Ruixin Li
    Ziwei Huang
    Zhaozhen Wu
    Haitao Tao
    Sujie Zhang
    Yi Hu
    [J]. Scientific Reports, 10
  • [6] 3-Year Overall Survival for Patients with Advanced NSCLC Treated with Pembrolizumab
    Hellmann, Matthew D.
    Leighl, Natasha B.
    Hui, Rina
    Carcereny, Enric
    Felip, Enriqueta
    Ahn, Myung-Ju
    Eder, Joseph Paul
    Balmanoukian, Ani S.
    Aggarwal, Charu
    Horn, Leora
    Patnaik, Amita
    Gubens, Matthew A.
    Ramalingam, Suresh S.
    Lubiniecki, Gregory M.
    Zhang, Jin
    Piperdi, Bilal
    Garon, Edward B.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 60 - 61
  • [7] Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC
    Cui, Pengfei
    Li, Ruixin
    Huang, Ziwei
    Wu, Zhaozhen
    Tao, Haitao
    Zhang, Sujie
    Hu, Yi
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [8] Efficacy and safety of pembrolizumab in patients with advanced adrenocortical carcinoma.
    Raj, Nitya Prabhakar
    Zheng, Youyun
    Kelly, Virginia
    Katz, Seth
    Chou, Joanne F.
    Do, Richard K. G.
    Capanu, Marinela
    Zamarin, Dmitriy
    Ariyan, Charlotte Eielson
    Untch, Brian R.
    O'Reilly, Eileen Mary
    Gopalan, Anuradha
    Berger, Michael F.
    Olino, Kelly
    Segal, Neil Howard
    Reidy, Diane Lauren
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Efficacy of immunotherapy in Chinese patients with KRASmutant advanced NSCLC
    Wang, Z.
    Han, X.
    Peng, L.
    Guo, J.
    Kong, L.
    Huang, Y.
    Tang, N.
    Zhang, J.
    Wang, M.
    He, X.
    Li, Z.
    Peng, Y.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1067 - S1067
  • [10] HEALTHCARE RESOURCE UTILIZATION IN PATIENTS RECEIVING PEMBROLIZUMAB OR DOCETAXEL WITH PREVIOUSLY TREATED ADVANCED NSCLC
    Huang, M.
    Pellissier, J.
    Liao, J.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A755 - A755
12345